If you are wondering whether DigitalBridge Group is still attractively priced after its recent run, looking closely at its valuation metrics can help you decide what the current share price really offers.
The stock last closed at US$15.41, with returns of 0.0% over 7 days, 0.4% over 30 days, 0.2% year to date, 43.9% over 1 year, 13.5% over 3 years, and a 36.3% decline over 5 years. Taken together, these figures give a mixed picture of how the market has treated the shares over different...
Global‑E Online (GLBE) has just posted its FY 2025 third quarter numbers, with revenue of US$220.8 million and basic EPS of US$0.08 on net income of US$13.2 million. This gives investors fresh data on how the cross border e commerce platform is converting top line scale into bottom line results. The company has seen quarterly revenue move from US$168.0 million in Q2 2024 to US$175.9 million in Q3 2024, then to US$189.9 million in Q1 2025, US$214.9 million in Q2 2025 and US$220.8 million in...
Danaher Corporation has agreed to acquire Masimo (NasdaqGS:MASI) in a definitive all cash transaction.
The deal terms value Masimo entirely in cash, with closing subject to customary approvals and conditions.
A legal investigation has been launched to assess whether the acquisition terms are fair to Masimo shareholders.
Masimo, known for patient monitoring and related medical technology, sits at the intersection of healthcare equipment and digital health tools. The proposed acquisition by...
Fiverr International (FVRR) just posted its FY 2025 numbers with Q3 revenue of US$107.9 million and basic EPS of US$0.15, set against trailing twelve month revenue of US$427.4 million and EPS of US$0.62 that reflect earnings growth of 121.2% over the past year. The company has seen quarterly revenue move from US$94.7 million in Q2 2024 to a range of roughly US$107 million to US$108.6 million across the first three quarters of 2025. Over the same 2025 periods, basic EPS shifted from US$0.09 in...
Prenetics Global (NasdaqGM:PRE) has just posted its FY 2025 third quarter numbers, with revenue of US$23.6 million and a basic EPS loss of US$0.40, keeping the company in loss-making territory. The company’s quarterly revenue has moved from US$10.5 million in Q4 2024 to US$17.3 million in Q1 2025, US$15.0 million in Q2 2025 and now US$23.6 million in Q3 2025. Over the same period, EPS losses have shifted from US$1.28 to US$0.80, US$0.64 and US$0.40. Investors are likely to weigh these results...
Wall Street brokerages have started coverage of EquipmentShare.com after its recent IPO, focusing on the company’s technology driven rental model.
Analysts are highlighting EquipmentShare’s plans to expand its rental footprint and its capital light approach to fleet growth.
The new coverage is drawing attention to the company’s goal of doubling rental locations and its position in the equipment rental industry.
EquipmentShare.com, listed on NasdaqGS:EQPT, is coming onto more investors’...
Waters Corporation (NYSE:WAT) introduced new high-sensitivity liquid chromatography columns featuring MaxPeak Premier Technology.
The company completed a realignment of its operations into four focused divisions aimed at adjacent high-growth markets.
Waters, a long-established player in analytical instruments and laboratory solutions, is using this product launch and business realignment to sharpen its role in analytical sciences and diagnostics. The new columns with MaxPeak Premier...
Liberty Global (LBTY.A) has reported another tough set of numbers for FY 2025, with Q3 revenue of US$1,207.1 million and a basic EPS loss of US$0.27, alongside trailing 12 month revenue of US$4.8 billion and a basic EPS loss of US$5.47. Over recent periods, the company has seen revenue move from US$1,069.5 million in Q3 2024 to US$1,207.1 million in Q3 2025, while EPS has shifted from a loss of US$4.0 in Q3 2024 to a loss of US$0.27 in Q3 2025. Overall, the latest figures keep the spotlight...
DRDGOLD (NYSE:DRD) has put up another firm set of numbers for H1 2026, with H2 2025 revenue at R4.1b and basic EPS of R14.76 sitting on top of R1.3b in net income, while the trailing twelve month line shows revenue of R7.9b and basic EPS of R26.01 backed by R2.2b in net income. The company has seen revenue move from R3.3b in H2 2024 to R3.8b in H1 2025 and then R4.1b in H2 2025, alongside basic EPS stepping from R8.58 to R11.26 and then R14.76. This progression sets a clear earnings rhythm...
Elite Pharmaceuticals (ELTP) just posted its Q3 2026 numbers, with revenue of US$31.6 million, basic EPS of US$0.017, and net income of US$18.6 million, while on a trailing twelve month basis revenue sits at US$140.1 million and EPS at US$0.040. Over the past few quarters, the company has seen revenue move between US$14.4 million and US$40.2 million per quarter, with basic EPS ranging from a loss of US$0.010 to a profit of US$0.018, and trailing twelve month EPS shifting from a loss of...
Caesars Entertainment (CZR) closed out FY 2025 with fourth quarter revenue of US$2.9 billion, a basic EPS loss of US$1.23 and a net income loss of US$250 million, compared with revenue of US$2.8 billion, basic EPS of US$0.05 and net income of US$11 million in the same quarter a year earlier. Over the past year, the company has seen quarterly revenue range from US$2.8 billion to US$2.9 billion, while basic EPS moved from a US$0.27 loss in Q3 2025 to a US$1.23 loss in Q4 2025. Trailing twelve...
MKS (MKSI) has wrapped up FY 2025 with Q4 revenue of US$1.0b and basic EPS of US$1.60, alongside trailing twelve month revenue of US$3.9b and EPS of US$4.38 that sit against a 55.3% earnings lift over the past year. The company has seen quarterly revenue move from US$934m in Q4 2024 to US$1.0b in Q4 2025, while basic EPS shifted from US$1.35 to US$1.60 over the same period. Analysts are forecasting 27.9% annual earnings growth and higher net profit margins, keeping investor attention firmly...
NewAmsterdam Pharma has begun late stage RUBENS Phase 3 trials of obicetrapib in patients with Type 2 diabetes and metabolic syndrome.
The company also plans to launch a new trial of obicetrapib in early Alzheimer's disease.
These programs expand obicetrapib's potential use into major cardiometabolic and neurological conditions.
For investors watching NasdaqGM:NAMS, these trial moves come as the stock trades at $35.24 and has returned 75.8% over the past year and 237.2% over the past five...
If you are trying to figure out whether Bitgo Holdings at around US$10.87 is a bargain or a value trap, starting with a clear view of what the current price reflects can help you frame the opportunity and the risks.
The stock has seen a 1.4% decline over the last 7 days and a 41.2% decline year to date, which can change how the market views its growth potential and risk profile.
Recent coverage around Bitgo Holdings has focused on its role in digital asset custody and broader crypto market...
As February begins, major U.S. stock indexes have shown strong performance, with the Dow Jones Industrial Average climbing 515 points and the S&P 500 nearing a record high. Amid this positive momentum, investors may find opportunities in stocks that appear to be trading below their estimated fair value, potentially offering attractive entry points in a market characterized by robust gains and evolving economic conditions.
